Recital 8, Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 20…

In forcesince 31 Mar 2004cited 1×

With a view to harmonising the internal market for new medicinal products, this procedure should also be made compulsory for orphan medicinal products and any medicinal product for human use containing an entirely new active substance, i.e. one that has not yet been authorised in the Community, and for which the therapeutic indication is the treatment of acquired immune deficiency syndrome, cancer, neurodegenerative disorder or diabetes. Four years after the date of entry into force of this Regulation, the procedure should also become compulsory for medicinal products for human use containing a new active substance, and for which the therapeutic indication is for the treatment of auto-immune diseases and other immune dysfunctions and viral diseases. It should be possible to review the provisions in point 3 of the Annex via a simplified decision-making procedure not earlier than four years after the entry into force of this Regulation.

  • Judgment of the Court (Third Chamber) of 22 June 2023. Federal Republic of Germany v European Commission.Decision

    Recitals 7, 8 and 19 of Regulation No 726/2004 state: Experience gained since the adoption of Council Directive 87/22/EEC of 22 December 1986 on the approximation of national measures relating to the placing on the market of …

    22 Jun 2023 · 62021CJ0006